Fenbendazole shows consistent anti-cancer activity in cell lines and animal models across numerous cancer types — including drug-resistant variants — through multiple mechanisms, but no controlled clinical trial has taken place yet. Consequently, the only human evidence consists of heavily confounded case reports and anecdotal accounts that cannot be attributed to fenbendazole alone.
Disclaimer: This article is for informational and educational purposes only. We are not medical professionals and do not provide medical advice. Neither fenbendazole nor mebendazole is approved by the FDA for cancer treatment. Always consult your physician or oncologist before considering changes to your treatment plan.
Abstract
Fenbendazole, a benzimidazole anthelmintic, demonstrates reproducible anti-proliferative activity against human cancer cell lines across a wide range of histological types, with IC50 values commonly in the low micromolar range and sub-micromolar sensitivity in select lines such as HT-29 colorectal (IC50 0.02 µM) [1], paraganglioma PTJ64i (IC50 0.10 µM) [1], and HeyA8 ovarian cancer (IC50 71.6 nM) [2]. Experimentally demonstrated mechanisms include G2/M cell cycle arrest [3–5], mitochondrial apoptosis with caspase-3/PARP activation [3, 6], proteasome inhibition [6], ROS production [7, 8], p53 stabilization via Mdm2/MdmX downregulation [9], glucose transporter suppression [10], and cancer stem cell inhibition [5]. In animal xenograft models using improved formulations, fenbendazole has shown tumor growth inhibition, prolonged survival, and retained activity against paclitaxel-resistant and 5-FU-resistant cancer variants [3, 11, 12]. However, orally administered unformulated fenbendazole frequently fails to achieve in vivo tumor activity in mouse models due to poor aqueous solubility (~0.3 µg/mL) and limited systemic bioavailability [12, 13], and one pharmacokinetic analysis concluded that systemic anticancer efficacy from standard oral dosing is not expected [14].
The human-level evidence is confined to a large number of uncontrolled case reports and widely circulated anecdotal accounts. Most notably, the self-treatment story of a small cell lung cancer patient who also received an experimental drug in a concurrent clinical trial [10, 15], and four published case reports describing tumor imaging improvements in DLBCL, renal cell carcinoma, urothelial carcinoma, and bladder cancer — all involving concurrent treatments that preclude attribution to fenbendazole [16, 17]. Because it is a veterinary drug, no randomized controlled trial or prospective clinical study of fenbendazole in cancer patients has been conducted [10, 16, 18], and fenbendazole is not approved for human use by the FDA or EMA [16]. The existing evidence supports a mechanistically plausible and preclinically active anti-cancer compound, but does not establish that fenbendazole offers demonstrable cancer-fighting benefit to human patients at currently used anecdotal dosing regimens; controlled clinical trials using bioavailability-optimized formulations are required to determine whether preclinical activity translates to human efficacy [5, 16, 19].
Paper search
We performed a semantic search across over 138 million academic papers. We retrieved 500 papers most relevant to the query for screening.
